Evaluation of Bisantrene Hydrochloride in Refractory Malignant Melanoma

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. [PMID18235113]

EL Korn;PY Liu;SJ Lee;JAW Chapman;D Niedzwiecki;VJ Suman;J Moon;VK Sondak;MB Atkins;EA Eisenhauer;W Parulekar;SN Markovic;S Saxman;JM Kirkwood Journal of Clinical Oncology 26(4):527-534

Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials

JM Unger;LE Flaherty;PY Liu;KS Albain;VK Sondak Cancer 91(6):148-1155

Survival and response to treatment in patients (pts) with metastatic melanoma from intraocular primaries (MMIP) on SWOG studies.

K Katato;PY Liu;V Sondak;LE Flaherty ASCO 14:410(#1298)

Phase II evaluation of bisantrene hydrochloride in refractorymalignant melanoma. A Southwest Oncology Group study.

DS Alberts;N Mason-Liddil;SJ Green;JD Cowan;WS Fletcher;B Neilan;JT Guy;RB Epstein Invest New Drugs 5:289-292

Southwest Oncology Group studies with Bisantrene.

CA Coltman Jr;D Cowan;DD Von Hoff;GM Durie;TP Miller;E Surwit;DS Alberts;RA Shildt;F Panettiere;GM Mills;PB Wasserman;TM McDaniel In: 13th International Congress of Chemotherapy (Vienna, August 28-September 2, 1983). KH Spitzy, K Karrer, eds. Symposium Bisantrene 213:1-4